Evidence map›Paper›PMID 30689639›Full record

ArticlePLoS neglected tropical diseases2019

A novel cell-free method to culture Schistosoma mansoni from cercariae to juvenile worm stages for in vitro drug testing.

Sören Frahm, Anisuzzaman Anisuzzaman, Ulrich Fabien Prodjinotho, Nermina Vejzagić, Admar Verschoor, Clarissa Prazeres da Costa

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2023
    Article
  12. Review
  13. Helminth egg derivatives as proregenerative immunotherapies.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Sören FrahmInstitute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany.ORCID 0000-0002-5162-9859
Anisuzzaman AnisuzzamanInstitute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany.
Ulrich Fabien ProdjinothoInstitute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany.
Nermina VejzagićInstitute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany.
Admar VerschoorInstitute for Systemic Inflammation Research, Universität zu Lübeck, Lübeck, Germany.
Clarissa Prazeres da CostaInstitute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany.ORCID 0000-0001-7996-4838
Institute of Medical Microbiology and Hygiene · DEBangladesh Agricultural University · BDUniversity of Lübeck · DE

Funding

NIAID NIH HHS HHSN272201700014C
6 · The paper itself

Abstract

backgroundThe arsenal in anthelminthic treatment against schistosomiasis is limited and relies almost exclusively on a single drug, praziquantel (PZQ). Thus, resistance to PZQ could constitute a major threat. Even though PZQ is potent in killing adult worms, its activity against earlier stages is limited. Current in vitro drug screening strategies depend on newly transformed schistosomula (NTS) for initial hit identification, thereby limiting sensitivity to new compounds predominantly active in later developmental stages. Therefore, the aim of this study was to establish a highly standardized, straightforward and reliable culture method to generate and maintain advanced larval stages in vitro. We present here how this method can be a valuable tool to test drug efficacy at each intermediate larval stage, reducing the reliance on animal use (3Rs). METHODOLOGY/PRINCIPAL

findingsCercariae were mechanically transformed into skin-stage (SkS) schistosomula and successfully cultured for up to four weeks with no loss in viability in a commercially available medium. Under these serum- and cell-free conditions, development halted at the lung-stage (LuS). However, the addition of human serum (HSe) propelled further development into liver stage (LiS) worms within eight weeks. Skin and lung stages, as well as LiS, were submitted to 96-well drug screening assays using known anti-schistosomal compounds such as PZQ, oxamniquine (OXM), mefloquine (MFQ) and artemether (ART). Our findings showed stage-dependent differences in larval susceptibility to these compounds.

conclusionWith this robust and highly standardized in vitro assay, important developmental stages of S. mansoni up to LiS worms can be generated and maintained over prolonged periods of time. The phenotype of LiS worms, when exposed to reference drugs, was comparable to most previously published works for ex vivo harvested adult worms. Therefore, this in vitro assay can help reduce reliance on animal experiments in search for new anti-schistosomal drugs.

Indexed as

AnimalsArtemetherCercariaCulture Media, Serum-FreeDrug Evaluation, PreclinicalHumansMefloquineOxamniquinePraziquantelSchistosoma mansoniSchistosomiasis mansoniSchistosomicidesArtemetherCulture Media, Serum-FreeMefloquineOxamniquinePraziquantelSchistosomicides

Identifiers

PMID30689639
PMCPMC6375649
OpenAlexW2951409032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.